Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menactra versus Adacel in South Korean participants aged 11 to 55 years
2015-005181-33Phase 3
- Sponsor
- Sanofi
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of meningococcal A conjugate vaccine and acellular pertussis vaccine in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoints: Percentage of participants with seroconversion following vaccination with either Menactra or Adacel vaccine, Seroconversion rate higher than 60% for serogroups A, C, Y and W-135 after Menactra and 1 more.
02
Drugs
meningococcal A conjugate vaccineacellular pertussis vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2015-005181-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005181-33.